期刊文献+

冠心病合并心力衰竭患者血清脂联素水平变化 被引量:1

The changers of serum adiponectin levels in patients with coronary heart disease combined with congestive heart failure
下载PDF
导出
摘要 目的探讨冠心病合并心力衰竭患者血清脂联素水平的变化及其临床意义。方法选择冠心病患者60例、冠心病合并心力衰竭患者60例[其中心功能(NYHA)Ⅱ级18例、心功能Ⅲ级27例、心功能Ⅳ级15例]、健康对照组25例,测定血清脂联素并对其变化进行两两比较。结果冠心病合并心力衰竭患者血清脂联素为(14.22±5.34)mg/L;冠心病无心力衰竭组血清脂联素为(4.79±1.61)mg/L;健康对照组为(6.98±1.62)mg/L,两两比较差异有统计学意义(P〈0.01)。冠心病合并心力衰竭患者随着心功能分级的升高,血清脂联素水平也显著升高[NYHAII级为(9.25±2.71)mg/L,NYHAⅢ级为(13.72±3.38)mg/L,NYHAIV级为(18.0±6.72)mg/L,P〈0.01]。结论合并心力衰竭的冠心病患者血清脂联素水平是升高的,且随着心功能分级的升高,血清脂联素水平也明显升高。血浆脂联素可能参与冠心病及心力衰竭的发病机制,血清脂联素水平变化对心力衰竭的进展和程度有一定的指导意义。 Objective To investigated the changes and clinical significance of serum adiponectin levels in patients with coronary heart disease (CHD) combined with congestive heart failure (CHF). Methods The total 145 persons were divided into 3 groups, including coronary heart disease (CHD) 60 patients, coronary heart disease (CHD) combined with congestive heart failure (CHF) 60 patients(NYHA Ⅱ class 18 patients, NYHA Ⅲ class 27 patients, NYHA Ⅳ class 15 patients). The other 25 healthy people were taken as the contrals. The serum adipenectin of all people was tested and the changes of them were analyzed. Results The serum adipenectin levels were (14.22±5.34)rag/L, (4.79±1.61)mg/L and (6.98±1.62)mg/L respectively in patients with coronary heart disease (CHD) combined with congestive heart failure (CHF), coronary heart disease (CHD), and healthy control group, The serum adiponectin in the patients with CHD combined CHF was higher than in healthy control group (P〈0.01), and the serum adipenectin levels were significantly increased according to the severity of NYHA class in CHF group [ NYHA Ⅱ class (9.25±2.71 )rag/L, NYHA Ⅲ class ( 13.72±3.38 )mg/L, NYHA Ⅳ class ( 18.0±6.72 )mg/L, P〈0.01 ]. Conclusion Serum adipenectin levels may be involved in the pathogenesis of CHD and CHF. The change of the serum adiponenctin is possibly valuable for evaluating the heart function and the prognosis of CHF.
出处 《中国心血管病研究》 CAS 2009年第6期432-434,共3页 Chinese Journal of Cardiovascular Research
关键词 冠状动脉粥样硬化性心脏病 心力衰竭 充血性 脂联素 Coronary heart disease Heart failure, congestive Adiponectin
  • 相关文献

参考文献3

二级参考文献28

  • 1李光伟,Step.,L.检测人群胰岛素敏感性的一项新指数[J].中华内科杂志,1993,32(10):656-660. 被引量:2125
  • 2[1]Scherer PE,Williams S,Fogliano M,et al.A novel serum protein similar to Clq,produced exclusively in adipocytes.J Biol Chem,1995,270:26746-26749.
  • 3[2]Fruebis J,Tsao TS,Javorschi S,et al.Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice.ProcNatl Acad Sci USA,2001,98:2005-2010.
  • 4[3]Tomas E,Tsao TS,Saha AK,et al.Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain:acety1-CoA carboxylase inhibition and AMP-activated protein kinase activation.Proc Natl Acad Sci USA,2002,99:16309-16313.
  • 5[4]Yamauchi T,Kamon J,Mizokoshi Y,et al.Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMPactivated protein kinase.Nat Med,2002,8:1258-1259.
  • 6[5]Ouchi N,Kihara S,Arita Y,et al.Adipocyte derived plasma protein adiponectin,suppresses lipid accumulation and class A scavenger receptor expression in human monocyte derived macrophages.Circu-lating,2001,103:1057-1063.
  • 7[7]Poulter N.Coronary heart diaease is a mulfifactorial disease.Am J Hypertens,1999,12:S92-S95.
  • 8[8]Philip KG,Gregorio D,Lu T,et al.Adiponectin expression from human adipose tissue:relation to obesity,insulin resistance and tumour necrosis-αexpression.Diabetes,2003,52:1779-1785.
  • 9Arita Y, Kihara S, Ouchi N,et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity.Biochem Biophys Res Commun, 1999, 257: 79-83.
  • 10Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specificprotein, adiponectin. in type 2 diabetic patients. Arterioscler Thromb Vase Biol,2000, 20:1595-1599.

共引文献52

同被引文献17

  • 1Jensen NS.Obesity and cardiovascular disease:is body structure a factor? Curr Opin Lipidol,1997,8:200-204.
  • 2Langle Y,Lodillinsky C,Belgoroky D,et al.Role of peroxisome proliferator activated receptor-gamma in bacillus CalmetteGuérin bladder cancer therapy.J Urol,2012,188:2384-2390.
  • 3Jung UJ,Torrejon C,Chang CL,et al.Fatty acids regulate endothelial lipase and inflammatory markers in macrophages and in mouse aorta:a role for PPARγ.Arterioscler Thromb Vasc Biol,2012,32:2929-2937.
  • 4Ziemke F,Mantzoros CS.Adiponectin in insulin resistance lessons:from translational research.Am J Clin Nutr,2010,91:S258-261.
  • 5Kusminski CM,Scherer PE.The road from discovery to clinic:adiponectin as a biomarker of metabolic status.Clin Pharmacol Ther,2009,86:592-595.
  • 6Monsalve FA,Pyarasani RD,Delgado-Lopez F,et al.Peroxisome proliferator-activated receptor targets for the treatment of metabolic diseases.Mediators of Inflammation,2013,17:18.
  • 7Higashi Y,Holder K,Delafontaine P,et al.Thiazolidinediones up-regulate insulin-like growth factor-1 receptor via a peroxisome proliferator-activated receptor gamma-independent pathway.J Biol Chem,2010,285:36361-36368.
  • 8Eldor R,DeFronzo RA,Abdul-Ghani M,et al.In vivo actions of peroxisome proliferator-activated receptors:glycemic control,insulin sensitivity,and insulin secretion.Diabetes Care,2013,36:S162-174.
  • 9Xu Y,Yang X,Wang Z,et al.Estrogen sulfotransferase (SULT1E1) regulates inflammatory response and lipid metabolism of human endothelial cells via PPARγ.Mol Cell Endocrinol,2013,369:140-149.
  • 10Pelham CJ,Keen HL,Lentz SR,et al.Dominant negative PPARγ promotes atherosclerosis,vascular dysfunction,and hypertension through distinct effects in endothelium and vascular muscle.Am J Physiol Regul Integr Comp Physiol,2013,304:R690-701.

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部